AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Tyra Biosciences, Inc.
Video analysis: TYRA
All videosNo video analysis for this stock yet. Request one from our team.
News: TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Sept. 10, 2026NEW YORK, Sept.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA's planned registrational adjuvant development strategy.
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference: Cantor Global Healthcare Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ETLocation: New York, NY A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
